Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD

References

• Vos T, Flaxman AD, Naghavi M. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:163-96
   Google Scholar
• Srivastava K, Thakur D, Sharma S, et al. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. PharmacoEconomics 2015;33:467-88
   PubMed Web of Science ®Google Scholar
• Laurendeau C, Chouaid C, Roche N, et al. [Management and costs of chronic pulmonary obstructive disease in France in 2011.]. Rev Mal Respir 2015;32:682-91
   PubMed Web of Science ®Google Scholar
• Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest 2015;147:31-45.
   PubMed Web of Science ®Google Scholar
• O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2014;70:376–8
   PubMed Web of Science ®Google Scholar
• Mestre-Ferrandiz J, Sussex J, Towse A. The R&D cost of a new medicine. London: University College, 2012
   Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203-14
   PubMed Web of Science ®Google Scholar
• Berndt ER, Nass D, Kleinrock M, et al. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Aff (Millwood) 2015;34:245-5.
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J COPD 2008;3:71-88
   Google Scholar
• Health care cost quality and outcomes. In: Berger ML, Bingefors K, Hedbloom E, et al., eds. Lawrenceville, NJ: ISPOR lexicon. Lawrenceville, NJ: ISPOR, 2003
   Google Scholar
• Domínguez-Ortega J, Phillips-Anglés E, Barranco P, et al. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma 2014;24:1-23
   Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-342
   PubMed Web of Science ®Google Scholar
• Kirsch F. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. Expert Rev Pharmacoecon Outcomes Res 2015;15:301-16
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. Allergy 2008;63:1581-92
   PubMed Web of Science ®Google Scholar
• Einarson TR, Shear NH, Oh PI. Models for pharmacoeconomic analysis. Can J Clin Pharmacol 1997;4:25-9
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• FDA Department of Health and Human Services. Reference number 98-0012. Infliximab approval. Silver Spring, MD, USA, 1998. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107700.pdf. Accessed July 2015
   Google Scholar
• Li L, Das AM, Torphy TJ, et al. What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases. Pulm Pharmacol Ther 2002;15:409-16
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9
   PubMed Web of Science ®Google Scholar
• FDA Department of Health and Human Services. BLA STN 103976/0. Review of clinical safety data: original BLA submitted on June 2 2000. Silver Spring, MD, USA, 2000. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113458.pdf. Accessed July 2015
   Google Scholar
• Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141-8
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53
   PubMedGoogle Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843-8
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-76
   PubMed Web of Science ®Google Scholar
• Gerzeli S, Rognoni C, Quaglini S, et al. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Invest 2012;32:253-65
   PubMed Web of Science ®Google Scholar
• Miller E, Sears MR, McIvor A, et al. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007;14:269-7.
   PubMed Web of Science ®Google Scholar
• Single technology appraisal (STA). Manufacturer submission of evidence. Camberley, UK: Novartis Pharmaceuticals presentation to NICE, 2007. www.nice.org/nicemedia/live/11686/37589/37589.pdf. Accessed July 2015
   Google Scholar
• Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265-9
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martínez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma 2013;50:410-18
   PubMed Web of Science ®Google Scholar
• Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics 2002;20:183-94
   PubMed Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342-8
   PubMedGoogle Scholar
• Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:1146-52
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667-77
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2:169-76
   PubMedGoogle Scholar
• Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009;103:12-21
   PubMed Web of Science ®Google Scholar
• Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009;15:226-32
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the evaluation of health care programmes. 3rd edn. Oxford, UK: Oxford University Press, 2006
   Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Respir J 2004;13:113
   Google Scholar
• Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-7
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Complete life tables, Ontario, 1995–1997. Secondary complete life tables, Ontario, Ottawa, Ontario, CANADA, 1995–1997. 2007
   Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
   PubMed Web of Science ®Google Scholar
• Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 2003;R97:212-20
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving p[reference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ-5D indices. Heath Economics Group Discussion Paper Series 02/01. Sheffield, UK: University of Sheffield School of Health and Related Research (ScHARR), Whiterose, University Consortium, Sheffield UK, May 2002
   Google Scholar
• Sullivan SD, Buxton M, Andersson LF, et al. Costeffectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003;112:1229-36
   PubMed Web of Science ®Google Scholar
• Garattini L, Catelnuovo E, Lanzeni D, et al. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmacoeconomia e Percorsi Terapeutici 2003;4:109-14
   Google Scholar
• Papi A, Paggiaro P, Nicolini G. ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62:1182-8
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Kotchie RW, Mörk AC, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ 2014;15:69-82
   PubMed Web of Science ®Google Scholar
• De Marco R, Locatelli F, Cazzoletti L. Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respir Res 2005;16:6-95
   Google Scholar
• Vogelmeier C, D’Urzo A, Pauwels R. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-28
   PubMed Web of Science ®Google Scholar
• Lanier B, Marshall GDJ. Unanswered questions on omalizumab (Xolair) patient selection and follow-up. Ann Allergy Asthma Immunol 2004;92:198-200
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7. http://dx.doi.org/10.3132/pcrj.2007.00002. Accessed July 2015
   PubMedGoogle Scholar
• de Vries F, Setakis E, Zhang B, et al. Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010;36:494-502. http://dx.doi.org/10.1183/09031936.0124209. Accessed July 2015
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
   PubMed Web of Science ®Google Scholar
• Kavuru M, Melamed J, Gross G. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16
   PubMed Web of Science ®Google Scholar
• Hoskins G, Smith B, Thomson C. The cost implications of an asthma attack. Pediatr Asthma Allergy Immunol 1998;12:193-8
   Google Scholar
• Paltiel AD, Fuhlbrigge AL, Fitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mildto- moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:39-46
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004;(3):CD003559
   Google Scholar
• Corren J, Casale T, Deniz Y, et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90
   PubMed Web of Science ®Google Scholar
• Niebauer K, Dewilde S, Fox-Rushby J, et al. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006;96:316-26
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
   PubMed Web of Science ®Google Scholar
• Briggs AH, Lozano-Ortega G, Spencer S, et al. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006;9:227-35
   PubMed Web of Science ®Google Scholar
• Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010;35:532-9
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008;15:437-43
   PubMed Web of Science ®Google Scholar
• Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J 2001;8:27-33
   PubMedGoogle Scholar
• Dalal AA, St Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis 2010;9:179-87
   Google Scholar
• Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010;19:68-74
   PubMedGoogle Scholar
• Oostenbrink JB, Rutten-van Mölken MPMH, Monz BU. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46 http://dx.doi.org/10.1111/j.524-4733.2005.03086.x. Accessed July 2015
   PubMed Web of Science ®Google Scholar
• Hettle R, Wouters H, Ayres J, et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respir Med 2012;106:1722-33
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Al MJ, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008;11:1070-80
   PubMed Web of Science ®Google Scholar
• Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003;25:285-97
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Al MJ, Beeh KM, et al. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J 2013;41:556-64
   PubMed Web of Science ®Google Scholar
• Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003;97:20-6
   PubMed Web of Science ®Google Scholar
• Karabis A, Mocarski M, Eijgelshoven I, et al. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years. Clinicoecon Outcomes Res 2014;5:175-85
   Google Scholar
• Lee KH, Phua J, Lim TK. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir Med 2006;100:2190-6
   PubMed Web of Science ®Google Scholar
• Lofdahl CG, Ericsson A, Svensson K, et al. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics 2005;23:365-75
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22:1599-607
   PubMed Web of Science ®Google Scholar
• Mittmann N, Hernandez P, Mellström C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. PharmacoEconomics 2011;29:403-14
   PubMed Web of Science ®Google Scholar
• Naik S, Kamal KM, Keys PA, et al. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2010;2:25-36
   PubMedGoogle Scholar
• Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63:962-7
   PubMed Web of Science ®Google Scholar
• Neyt M, Devriese S, Thiry N, et al. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med 2010;10:47. doi: 10.1186/471-2466-10-47.
   PubMed Web of Science ®Google Scholar
• Nielsen R, Kankaanranta H, Bjermer L, et al. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respir Med 2013;107:1709-21
   PubMed Web of Science ®Google Scholar
• Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007;82:575-82
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Mullins CD, DeLisle S. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Value Health 2008;11:980-8
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Mölken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241-9
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst AP. Improved health outcomes in patients with COPD during 1 year9s treatment with tiotropium. Eur Respir J 2002;19:209-16
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Mölken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46
   PubMed Web of Science ®Google Scholar
• Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011;105:1635-47
   PubMed Web of Science ®Google Scholar
• Price D, Asukai Y, Ananthapavan J, et al. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy 2013;11:259-74
   PubMedGoogle Scholar
• Price D, Keininger D, Costa-Scharplatz M, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med 2014;108:1786-93
   PubMed Web of Science ®Google Scholar
• Asukai Y, Baldwin M, Fonseca T, et al. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. PharmacoEconomics 2013;31:151-61
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-35
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007;25:695-711
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis 2013;8:79-87
   PubMed Web of Science ®Google Scholar
• Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-31
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics 2005;23:619-37
   PubMed Web of Science ®Google Scholar
• Van Der Palen J, Monninkhof E, Van Der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006;61:29-33
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67
   PubMed Web of Science ®Google Scholar
• Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997;156:1719-24
   PubMed Web of Science ®Google Scholar
• Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9
   PubMedGoogle Scholar
• Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006;5:343-9
   PubMedGoogle Scholar
• Nurmagambetov T, Atherly A, Williams S, et al. What is the cost to employers of direct medical care for chronic obstructive pulmonary disease? COPD 2006;3:203-9
   PubMedGoogle Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Luccioni C, Donner CF, De Benedetto F. I costi della broncopneumonopatia cronica ostruttiva: la fase prospettica dello studio ICE (Italian costs for exacerbations in COPD). Pharmacoeconomics (Italian Research Articles) 2005;7:119-34
   Google Scholar
• Dal Negro RW, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003;97:S43-50
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24. http://dx.doi.org/10.1183/09031936.02.0269802. Accessed July 2015
   PubMed Web of Science ®Google Scholar
• Britton M. The burden of COPD in the UK: results from the Confronting COPD survey. Resp Med 2003;97(C Suppl):S71-9. http://dx.doi.org/. Accessed July 2015
   Google Scholar
• Griffiths TL, Phillips CJ, Davies S, et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001;56:779-84
   PubMed Web of Science ®Google Scholar
• Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis 2012;7:183-99
   PubMed Web of Science ®Google Scholar
• Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011;3:107-29
   PubMedGoogle Scholar
• Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmacoeconomic evaluations in Belgium. Health technology assessment (HTA) Brussels: Health Care Knowledge Centre (KCE), 2008. p.78C
   Google Scholar
• Dahl R, Greefhorst LA, Nowak D. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84
   PubMed Web of Science ®Google Scholar
• Rodriguez Roisin R, Rabe KF, Anqueto A. Workshop report: Global strategy for the diagnosis, management and prevention of COPD: updated 2009. Global Initiative for Chronic Obstructive Pulmonary Disease, MD USA, www.goldcopd.com. Accessed April 2012
   Google Scholar
• Koopmanschap MA, Rutten FF, van Ineveld BM. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89
   PubMed Web of Science ®Google Scholar
• Boyd G, Morice AH, Pounsford JC. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9:90-101
   PubMedGoogle Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40
   PubMedGoogle Scholar
• Rutten-van Molken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:630-4
   PubMedGoogle Scholar
• Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011;14:315-23
   PubMedGoogle Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26
   PubMed Web of Science ®Google Scholar
• Donohue JF, van Noord A, Bateman ED. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD Patients treated with tiotropium or salmeterol. Chest 2002;122:47-55
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen K, Fergusson D. The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment. Can Respir J 2004;11:581-5
   PubMedGoogle Scholar
• Aaron SD, Vandemheen KL, Fergusson D. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar
• O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007;61:1112-20
   PubMed Web of Science ®Google Scholar
• Roede BM, Bindels PJ, Brouwer HJ, et al. Antibiotics and steroids for exacerbations of COPD in primary care: compliance with Dutch guidelines. Br J Gen Pract 2006;56:662-5.
   PubMed Web of Science ®Google Scholar
• Pennachio DL. Exclusive survey. Fees and reimbursements. Med Econ 2003;80:96-109
   PubMedGoogle Scholar
• Oostenbrink JB, Buijs-Van Der Woude T, et al. Unit costs of inpatient hospital days. PharmacoEconomics 2003;212:63-71
   Google Scholar
• Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high cost exacerbations of COPD. Respir Med 2004;98:883-91
   PubMed Web of Science ®Google Scholar
• Paterson C, Langan CE, McKaig GA. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and Euro-Qol (EQ-5D). Qual Life Res 2000;9:521-7
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93
   PubMed Web of Science ®Google Scholar
• Donohue J, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol vs. tiotropium. Am J Respir Crit Care Med 2010;155:e62
   Google Scholar
• Kornmann O, Dahl R, Centanni S. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo controlled comparison. Eur Respir J 2011;37:273-9
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005;11:121-8
   PubMed Web of Science ®Google Scholar
• Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005;3:56
   PubMedGoogle Scholar
• Kornmann O, Dahl R, Centanni S. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, Hoogendoorn M, Lamers L. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. PharmacoEconomics 2009;27:465-77
   PubMed Web of Science ®Google Scholar
• Dahl R, Jadayel D, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD 2013;8:501e8
   Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeteroldfluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;51:e60
   Google Scholar
• Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91
   PubMed Web of Science ®Google Scholar
• Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002;122:1994-2002
   PubMed Web of Science ®Google Scholar
• Jansson SA, Backman H, Stenling A, et al. Health economic costs of COPD in Sweden by disease severity has it changed during a ten years period? Respir Med 2013;107:1931-8
   PubMed Web of Science ®Google Scholar
• Lindberg A, Larsson LG, Muellerova H, et al. Up-to-date on mortality in COPD e report from the OLIN study. BMC Pulmonary Med 2012;12:1
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity Stages? Chest 2006;130:1117-28
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387-95
   PubMed Web of Science ®Google Scholar
• Badia X, Roset M, Herdman M, et al. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001;21:7-16
   PubMed Web of Science ®Google Scholar
• Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting β2 agonists for COPD: influence of exacerbation history. Eur Respir 2011;38:553-60
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. PharmacoEconomics 2009;27:465-77
   PubMed Web of Science ®Google Scholar
• Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67
   PubMed Web of Science ®Google Scholar
• Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6:98. doi:10.1186/465-9921-6-98
   PubMed Web of Science ®Google Scholar
• Prescott-Clarke P, Primatesta P. Health survey for England 1996. 2: London, 1998
   Google Scholar
• Brazier J, Usherwood T, Harper R. Deriving a preference based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28
   PubMed Web of Science ®Google Scholar
• Hoogedorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health 2014;17:525-36
   PubMed Web of Science ®Google Scholar